Theratechnologies Inc. Overview
Pro stress-test →Theratechnologies was acquired by Future Pak in September 2025 for US$3.01 per share in cash plus contingent value rights. The specialty biopharmaceutical company addressed unmet medical needs in the HIV patient community with prescription products focused on HIV-associated lipodystrophy and multidrug-resistant HIV-1 infections.
Strategic Profile
Pro stress-test →The company had two approved products: EGRIFTA (marketed in Canada and the United States) and Trogarzo (approved for commercialization in the United States). In October 2023, the company reduced R&D activities with plans to pursue future clinical research in oncology and NASH through partnership deals.
Competitive Landscape
Pro stress-test →Direct competitors in HIV treatment include Gilead Sciences (with products like Bictegravir/TAF) and ViiV Healthcare (GSK subsidiary). Indirect competitors address HIV-associated complications and multidrug-resistant infections. The acquisition integrates Theratechnologies into Future Pak's contract manufacturing platform, shifting competitive positioning.
Industry Context
Theratechnologies Inc. operates in HIV-focused specialty pharmaceuticals.
Key facts
Founded: 1977 · Headquarters: Montreal, Canada